Currently included on this page are:
Hepatitis C - whole genome sequencing (WGS) now available
HEE Report Launch - Tackling antimicrobial resistance: the role of formative assessments
UK SMI TP 5: bile solubility test
Reviewing Specialised Infectious Diseases Services in England
BIA CSC Position Statement on the determination of Consultant Competence
Tackling antimicrobial resistance - educational priorities
NCEPOD - call for study proposals
UK SMI V 4: investigation of hepatitis B infection
SaBTO Microbiological Safety Guidelines
Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C
2018 National AMR Campaign
Healthcare professional survey - pharma communications strategies
Immediate ART for treatment of HIV-1 in adults and adolescent
Scientists at Public Health England (PHE) have developed the first ever clinically validated whole genome sequencing test for hepatitis C virus (HCV) as part of a global effort to eliminate HCV by 2025. The assay looks at both viral genotype and drug resistance in one test. The new combined test took over 5 years to develop and will halve the current turnaround time for samples sent to PHE for resistance testing from 20 to 10 days. This enables those clinicians who use PHE Cloindale's HCV service to provide patients with quicker access to curative treatment plans. PHE hopes that as the first WGS test for viruses this will serve as a model for other viruses such as HIV. You can find out more about requesting a test here: http://www.gov.uk/guidance/antiviral-unit-avu-reference-services
Health Education England has surveyed the inclusion of competencies developed by the Government’s expert advisory committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) and Public Health England (PHE) into health professional curricula and the education approaches for the responsible prescribing of antimicrobials.
Within both these reports we made a recommendation that HEE will explore the feasibility of an individualised online formative assessment tool for health students and health professionals to support learning on infection prevention and control (IPC) and antimicrobial resistance (AMR) and stewardship (AMS).
Our report outlines the methodology in consulting stakeholders on this feasibility and the conclusions made in considering a system wide formative assessment. A number of learning resources are already available for different professional groups around antimicrobial resistance and stewardship and infection prevention and control.
Most professional groups do not have formal assessment processes to support learning on AMR/IPC/AMS. The term ‘individualised’ needs defining with a clear scope on whether individuals or professional groups will be targeted in different working environments and stages in their career
HEE will consider outcomes from this work, that will inform the future direction of our antimicrobial resistance and sepsis programme.
This SMI was reissued on 13 August 2018
Click for gov.uk webpage
NHS England is responsible for nationally commissioning specialised services to deal with a range of infectious diseases (ID). Some of the more common diseases, such as HIV and Hepatitis C have separate policies, so we are currently reviewing how we manage care for patients who have one of the other serious and rare infectious conditions, to ensure that people receive high quality, appropriate care while safeguarding against the spread of disease.
Late last year we held two engagement events with colleagues across the country to discuss some of the issues with current provision of specialised infectious disease services in order to begin looking at how we can commission these services more effectively. The key barrier to progressing our case for change has been the lack of data to support the need for a different commissioning model. Although we have plenty of anecdotal evidence that suggests we need a more planned and co-ordinated approach to managing specialised infection services, we do not have enough information about the way expertise and resources are used in order to meet the current, and potential, need.
We are now looking at ways to capture activity that would demonstrate how services operate more clearly, and are scoping plans for an electronic referral system which would track referrals and requests for advice or information, in a way that would give a clearer picture of the demands made upon specialised infection services. It is likely that we will recruit two or more test sites who would use this new system over the next few months, and we will be in touch with all Specialised Adult Infectious Disease Centres to share more detail on these plans in the next few weeks.
If you would like to receive these updates directly in order to find out about opportunities to get involved, please sign up as a registered stakeholder for the Infectious Diseases CRG (Clinical Reference Group) which comes under the Blood & Infection Programme of Care.
Infectious Diseases CRG (Clinical Reference Group)
Skipton House – 3B
80 London Road
London, SE1 6LH
We note that RCPath have also produced a position statement which was published on 10/07/2017. Both documents are entirely congruent.
This document was updated in January 2018; the updated version is available below.
In 2017 Health Education England committed to work with stakeholders to explore the factors that help or hinder education about antimicrobial resistance and to identify good practice materials for promotion. We asked those that train healthcare workers what works well in an educational environment, what the challenges are and how Health Education England might support the education of prudent, responsible use of antimicrobials
The report Tackling antimicrobial resistance – educational priorities explores perspectives about educational interventions that may help address antimicrobial resistance in different healthcare settings and barriers for implementation.
The themes in this report will inform the future direction of Health Education England’s antimicrobial resistance and sepsis programme.
NCEPOD's 2018 call for study proposals is open until 5th October 2018. We are inviting organisations to submit original study proposals, which will be considered as possible forthcoming studies. Study proposals should be relevant to the current clinical environment and, very importantly, should have the potential to contribute original work to the subject.
The last full scientific review of this document was completed on 7th June 2018.
Click for further information
A new revision of the guide to the microbiological safety of human organs, tissues and cells used in transplantation, now renamed as the SaBTO microbiological safety guidelines, has been published. The new guidelines are available on the SaBTO website.
NICE technology appraisal TA361 on simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) has been withdrawn because Janssen withdrew the marketing authorisation for simeprevir on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
The 2018 National AMR campaign was launched in March, and will run until September 2018.
This is a highly targeted national AMR awareness and educational campaign titled “Drug Resistance” in partnership with ESCMID, BIVDA and BSAC reaching key stakeholders such as Clinical Microbiologists, Government, CCG’s and the public. Details of the campaign, and its aim are below.
Campaign title: 2018 Drug Resistance (AMR)
Launch date: 9th of March running until September 2018
Format: Multi- platform campaign: 16-page print publication in the Guardian, online via www.globalcause.co.uk, events, conferences and via social media
Aim: To provide an educational, action and implementation campaign around antimicrobial resistance and the need to preserve the effectiveness of antibiotics
Target Audience: HCP’s (Clinical and non- clinical), Investors, policy makers, Industry and the public
Further information is available at www.globalcause.co.uk
Do you want to influence how you communicate with Pharma?
This survey is around pharma’s relationship with doctors and what they feel is appropriate / optimal in terms of content / channel of communication. The idea is to raise awareness in the pharmaceutical industry of how doctors want to be communicated with. The results of the survey will be published in the pharmaceutical press (pharmaphorum) as well as circulated through industry contacts. This is an opportunity for doctors to have a say in the way that they communicate with the pharma industry and should hopefully help to stimulate meaningful debate at a time where the relationship is somewhat strained.
Virtual Doctors is a small charity which provides email advice to rural health workers in Africa and is currently looking to recruit more volunteer doctors (especially infectious diseases) based in the UK. Anyone interested in helping - particularly trainees, as this may be a good learning opportunity - should refer to the Virtual Doctors website for more information.